Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) Director Muneer A. Satter purchased 60,000 shares of the stock in a transaction dated Thursday, December 6th. The stock was acquired at an average cost of $2.09 per share, with a total value of $125,400.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
OTCMKTS:ARPO opened at $2.08 on Friday. Aerpio Pharmaceuticals Inc has a 52 week low of $1.75 and a 52 week high of $5.50.
Aerpio Pharmaceuticals (OTCMKTS:ARPO) last posted its earnings results on Wednesday, November 7th. The company reported $0.28 EPS for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.06). The company had revenue of $18.82 million for the quarter, compared to the consensus estimate of $18.67 million.
A number of equities research analysts recently commented on ARPO shares. HC Wainwright set a $9.00 target price on shares of Aerpio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research cut shares of Aerpio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Finally, Guggenheim started coverage on shares of Aerpio Pharmaceuticals in a research report on Wednesday, September 19th. They set a “buy” rating and a $10.00 target price for the company.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.